Member Info for Saxondale

What a great day . Tempered by the fact that we should never have been anywhere in the teens again . I have a feeling we may have plenty more of these sorts of days to come .

Thats my thought CR - mild cases at home don't normally allow SNG001 to shine , but on Activ 2 maybe they've had a more serious mix of cases than the UK home trial allowing the drug to show its difference to placebo .
If thats the case , then like you say , the hospital based results will be streets ahead .

Mario you hero !!
Looks like Activ 2 P3 is happening then .
Fantastic news .
A Home study shows enough efficacy to progress .
Have I missed something or is this news not pretty massive ?

Never mind the White House , what time's Castro on ?
He can move the SP more than the President of the United States lol

When you log on in the morning and there's already 21 posts it either means a drunk argument at 1am , or there's something interesting afoot . Makes a nice change !

Castro is always good for 20-30p .
The man can't help himself .

Nice , a big investor loading up as trial results are looming can only be good .
They don't just add that much without plenty of research and due diligence .
It's one thing sticking with your investment , but adding at this critical juncture speaks volumes.

Although the successful candidate will be overseeing strategic clinical trial progression across a variety of therapy areas .
And collaborate with external parties.
Sounds like quite a responsible post , more than 'lab technician' .

A good start to building the team to bring these therapies a step closer to market .

Another job vacancy - this time Medical Director, Haematology/Immunology .

Perhaps to oversee the build up of the Haematokine program , although Bex will be running its Hematlogical malignacies Phase 1 trial this quarter - so plenty to be getting on with .

Key responsibilities

Provide medical expertise across the entire scope of the clinical development process
Participate in internal Clinical Development, Pharmacovigilance, Regulatory and Early Drug Development activities
Apply medical and clinical expertise to collaborate with external parties
Oversee strategic clinical trial progression across a variety of therapy areas

https://www.pharmarelations.com/available-positions?mtrpage=assignment&mtrid=501646

And at long last , perhaps Turku will no longer be known simply as the ' Contraceptive Capitol of the World '
This site was interesting - guess who is first on the list ?
Not saying its ranked 1-15 , but its not alphabetical..
https://www.labiotech.eu/best-biotech/biotech-companies-finland/
To celebrate the blossoming biotech industry in Finland, we consulted with experts to put together a list of the most remarkable companies in the country, be it for their size, innovation, or influence in the sector.

Interesting read this .
https://eic.ec.europa.eu/guide-applicants_en

The EIC gets thousands of applications for grants . Those are whittled down to a select few who they feel qualify best .

Faron have received firstly the maximum 2.5 million euro grant , then large equity investment , and now a further large equity investment . Their records are showing 10 million so far , although I feel that was before this latest placing . I'm not sure how they get to 10 million exactly but anyway thats what it says .

By the looks of it , you don't just phone them up the week before and see if they want to commit , you have to make a full application , which is evaluated by their large team of EIC Jury members ( quite a list )
https://eic.ec.europa.eu/eic-jury-members_en

The criteria covers in detail everything from whether your innovation has enough technological proof to back up what you are proposing and that the risk is acceptable .
Your innovation has to be novel , will make a broad impact on society , and have a team behind it that can deliver the goal .
Is there a convincing strategy for commercialisation. Have key partners for commercialisation been established.
Is the risk nature of your innovation such that market actors may not wish to provide the full amount alone .

It looks like there are various cut off dates for apllications , and for each funding round , you need to make an application to explain why you need the funds and what they will be used for .

Yes , we have a rich uncle in the form of Timo . He has been pivotal in the early days in helping build up and maintain a steady ownership of shares . including Markku , his family and Juho , they now own approx 25% of the company.

But the EIC isn't a rich uncle , and I assume there is fierce competition for these grants and investments .

Faron will still need funding in the future , but lets hope this placing gets us a bit higher up the ladder . Having this sort of backing has to be a good thing . The G20 invitation again has to be a good thing . Recognition in LBAs etc has to be a good thing . DofD funding has to be a good thing .

These bodies obviously feel that Faron's discoveries and work is worthwhile backing . Obviously the SP will react as more dillution always does , and yes we didn't command a high placing price as we are still in that limbo period of getting data and not having a package ready to sell or license.

Faron are now going to building up a team to prepare for commercialisation and further studies .
The funding question is now answered for the time being .
Onwards and upwards .

Two new study sites added to the Hibiscus trial . One in Massachusetts , one in Nashville
Now 6 in total .
And 5 are shown as recruiting ( was just one )
So we have sites in Massachusetts , Tennessee and Colorado now
So looks like things are picking up speed .

Hospitalisations are still at raised levels in Massachusetts ( 600 odd , with 158 in ICUs )
Of those 600 , a third are fully vaccinated .

That what I thought , until i saw it was euros .
About £3.30 ish
Still, its done now
News will get us up again.
Timo had another 5 million - now owns 16.7% - at least those are sticky hands , as is the EIC .

As always , us shareholders are always a bit behind the curve .
The EIC is buying possible another 5 million euros worth of Faron .
They have invested 10 million euros in Faron so far . One of of only 111 companies in Europe to receive EIC investment . And the ONLY company in Finland to be published as having received investment ( 2 or 3 others are in a larger list )
The most they can invest in a single company is 15 million euros , and if they put 5 in today , that will mean they have invested the maximum amount permissable .
I can see only one company so far that has received the maximum amount ( Calypso , in France )

From their blurb -
All investments are preceded by a thorough evaluation by external experts, a due diligence process overseen by the EIC Fund Investment Committee, and a final decision by the EIC Fund Board of Directors.

So they have obviously seen something they feel is worth continued investment .
And Faron feel this is the right way to go at this time , while so much new data is so tantalizingly close .

Its a journey at the end of the day - a journey towards jam .

https://eic.ec.europa.eu/eic-fund-equity-investments-beneficiaries_en

Looking at the differences between this placing and the last one in Feb

In Feb - looked to raise approximately 15 million euro
Today - looked to raise a minimum of 8 million euro

In Feb - EIC agreed to take a third . min 3 mill , max 10 mill . Looked for 15 - got 15
Today - EIC agreed to take a third . min 2 mill , max 5 mill . Looking for at least 8 . Could be a max of 15 based on EIC max

In Feb - Price was 4.26 euro ( a 5% discount on the 30 day vol weighted av price on the Nas )
Today - if the same that would probably come out at not far off where we are , actually maybe a bit higher .

It takes the SP back 6 months agreed , but it gives us fuel to push through into those areas where the money starts getting very serious .
such as -
A P2 completed with at least 5 cohorts qualifying for a pivotal progression.
A P2/3 trial underway in the US , funded mostly by the DofD
Data gathered on soluble clever-1 , and biomarker data that could prove transformational.
Three new trials on lung/neoadjuvant/hematological going into P1 in Q4 2021 .

Bex has been getting a lot of attention . The findings they make in the next few months could just heap multiples of value onto its potential .

Regarding the SSV , I always took it as his opinion at the time given what he knew .
Probably a mistake to put it out there to be honest , as it only came back to bite him .

Every share I own is a jam tomorrow share it seems . And even when you think you've got the jam , you open it up and there's another jar inside with a note in it it saying ' its coming tomorrow '.

Anyway , it looks like we're funded for the best part of a year , to find out loads more on Bex , maybe get Traumakine over the line , ramp up manufacturing , and maybe , just maybe , get some jam !

Well they are only gonna sell it once , so if we've got other interested parties , that is surely your perfect scenario when selling .
JORC to come next , then it'll be case of watch and wait .

CB , did he say no placement ? I know he avoided answering in any detail , I thought he just said its sorted .
Either way , its not much in the scheme of things if it gets us to the right destination .
Lord knows I need a boost in one of my shares sometime soon to cheer me up , been a sea of red with a blip of blue now and again .
Just gotta take it that this is the best way to go I guess . Lets see what the placing price is . Anything under £3.50 will be a bit of an insult.
I take some comfort from the continued EIC investment . They see a future with Bex , otherwise they wouldn't keep investing .

Well that explains the drop in the SP .
8 million euros to see us into the pivotal P3 trials and cover us to Q3 2022
I can fully understand it .

Perhaps its also a very shrewd move in regard to partnership discussions ( be they big Pharma or G20 )
Any potential suitor will now have to contend with the fact that Faron is now comfortably funded for almost another year .

Certainly puts Faron in a stronger place .

And the EIC again stepping up to be the biggest investor .
Essentially the EU putting more money into Faron .
Not a bad recommendation going into those G20 discussions in a weeks time .

I expect Timo will have a slice too perhaps.

He can't say anything in detail other than he is ' very pleased' with what they are seeing so far . That's good enough for me to understand .

Chief Development Officer, Dr Juho Jalkanen, will be presenting at the virtual Macrophage-directed Therapies Summit on Thursday September 30, 2021 at 2pm EST

Maija also presenting for Hollmen Lab regarding Bex and Breast and Ovarian cancer tumours . Day 2 12pm

Not sure we can gain access to this - as its a $2000 registration fee .